| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $20,158,255 ) (Continued on the next page) |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA262466 | Assessing DNA polymerase theta as a therapeutic target in BRCA1 mutant cancer | 001 | 4 | NIH | 6/3/2025 | $43,005 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R00CA267678 | Positive Activities for Asian American Cancer Patients and Caregivers | 000 | 4 | NIH | 3/12/2025 | $197,906 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD018146 | Examining the Relationship between Residential History at Midlife and Prostate Cancer Outcomes | 002 | 3 | NIH | 4/18/2025 | $512,007 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA248655 | Evidence-Based Approach to Empower Asian American Women in Cervical Cancer Screening | 001 | 6 | NIH | 5/22/2025 | $30,355 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA248655 | Evidence-Based Approach to Empower Asian American Women in Cervical Cancer Screening | 000 | 6 | NIH | 3/12/2025 | $273,211 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA281212 | Elucidating the critical role of Wee1 in GIST | 001 | 3 | NIH | 5/22/2025 | $43,005 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA281212 | Elucidating the critical role of Wee1 in GIST | 000 | 3 | NIH | 2/13/2025 | $387,045 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA289703 | Hepatic Tissue Integrity and Clonal Fitness: Key Factors in Controlling β-Catenin Induced Oncogenesis | 001 | 2 | NIH | 5/22/2025 | $53,165 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA289703 | Hepatic Tissue Integrity and Clonal Fitness: Key Factors in Controlling β-Catenin Induced Oncogenesis | 000 | 2 | NIH | 2/13/2025 | $478,491 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA289161 | NPC1 as a novel therapeutic target in ccRCC | 001 | 2 | NIH | 5/22/2025 | $26,367 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA289161 | NPC1 as a novel therapeutic target in ccRCC | 000 | 2 | NIH | 3/4/2025 | $237,303 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA296696 | Assessment of Efficacy and Toxicity of T3 for Medulloblastoma Treatment | 000 | 1 | NIH | 1/28/2025 | $219,351 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UH3CA271230 | Validation of blood-based predictive biomarkers of therapeutic response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer | 000 | 4 | NIH | 5/13/2025 | $470,000 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R37AI110985 | Regulation of hematopoiesis by ribosomal protein paralogs | 000 | 11 | NIH | 12/24/2024 | $690,669 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA283396 | Divergent Functions of ERK Substrate Binding Domains in Pathogenesis of Myeloproliferative Neoplasms | 000 | 3 | NIH | 7/1/2025 | $707,044 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA282766 | Interrogating MRCK Protein Kinases in Ovarian Cancer | 000 | 2 | NIH | 3/4/2025 | $406,720 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD017675 | Reducing Urban Cervical Cancer Disparities Using a Tailored mHealth Intervention to Enhance Colposcopy Attendance | 000 | 3 | NIH | 12/17/2024 | $624,082 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R03CA286669 | Divergent Functions of ERK2 Substrate Binding Domains in Pathogenesis of KRAS-Driven Pancreatic Cancer | 000 | 2 | NIH | 11/14/2024 | $94,000 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R00CA263017 | The role of MER/PROS1 in promoting stromal induced emergence from metastatic melanoma dormancy | 000 | 4 | NIH | 4/23/2025 | $224,100 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R00CA263017 | The role of MER/PROS1 in promoting stromal induced emergence from metastatic melanoma dormancy | 001 | 4 | NIH | 5/29/2025 | $24,900 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM150538 | Telomerase RNP Prisonbreaks from Phase-Separated Nuclear Body | 001 | 3 | NIH | 5/1/2025 | $470,000 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA271915 | Targeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancer | 005 | 4 | NIH | 7/10/2025 | $779,894 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA276273 | Fibroblasts Support the Growth of Brain Metastasis by Rendering Cancer Cells Resistant to Chemotherapy and Inducing Immunosuppression in Tumor Microenvironment | 000 | 3 | NIH | 6/3/2025 | $412,500 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R25CA288297 | Addressing the Training Gap in Oncology on Sexual Health: Development of the Sexual Health Integrative Fellowship Training (SHIFT) Course for Hematology-Oncology Fellows | 000 | 2 | NIH | 5/13/2025 | $161,299 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R03CA292552 | Pilot Studies of NN-01-195, a New Tumor-Targeted AURKA Inhibitor | 000 | 1 | NIH | 6/23/2025 | $186,000 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01AI171568 | Role of ZBP1 in pathogenesis of Salmonella biofilms | 000 | 3 | NIH | 4/25/2025 | $838,667 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA269975 | Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy | 001 | 3 | NIH | 6/12/2025 | $75,897 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA269975 | Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy | 000 | 3 | NIH | 1/6/2025 | $683,088 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA269660 | Pancreatic cancer-associated fibroblasts: function, detection, and regulation | 000 | 4 | NIH | 5/15/2025 | $539,269 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R25CA259244 | Empowering the Next Generation of Cancer Professionals: the Fox Chase Cancer Center-University of Delaware Partnership for Undergraduate Research and Career Development | 001 | 4 | NIH | 5/29/2025 | $15,174 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R25CA259244 | Empowering the Next Generation of Cancer Professionals: the Fox Chase Cancer Center-University of Delaware Partnership for Undergraduate Research and Career Development | 000 | 4 | NIH | 2/14/2025 | $136,564 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM144131 | Deciphering Networks Controlling DNA Amplification | 001 | 4 | NIH | 11/5/2024 | $420,750 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01GM141513 | Designing selective kinase inhibitors via deep learning | 000 | 4 | NIH | 11/21/2024 | $494,601 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R00CA276888 | Mechanisms and vulnerabilities of ERG-driven luminal fate in prostate cancer | 001 | 3 | NIH | 5/22/2025 | $24,899 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R00CA276888 | Mechanisms and vulnerabilities of ERG-driven luminal fate in prostate cancer | 000 | 3 | NIH | 4/30/2025 | $224,101 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA251674 | Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma | 000 | 5 | NIH | 6/13/2025 | $427,763 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA259188 | Investigating the IL-1R Pathway in Anaplastic Large Cell Lymphoma for Targeted Therapy | 001 | 5 | NIH | 5/26/2025 | $41,049 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA259188 | Investigating the IL-1R Pathway in Anaplastic Large Cell Lymphoma for Targeted Therapy | 000 | 5 | NIH | 4/10/2025 | $369,440 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA290043 | Thyroid Hormone Inhibits Medulloblastoma Growth by Inducing Tumor Cell Differentiation | 000 | 1 | NIH | 4/23/2025 | $559,587 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 001 | 56 | NIH | 5/8/2025 | $2,784,348 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD018511 | Neighborhood, social connectedness, and allostatic load in US Chinese immigrants | 001 | 3 | NIH | 4/24/2025 | $67,889 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD018511 | Neighborhood, social connectedness, and allostatic load in US Chinese immigrants | 000 | 3 | NIH | 12/13/2024 | $611,002 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA289629 | Targeting anoctamin 6 to disrupt trogocytosis of cancer-associated fibroblasts | 000 | 1 | NIH | 3/7/2025 | $642,755 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM122517 | Structural Bioinformatics of Proteins and Protein Complexes and Applications to Cancer Biology | 001 | 8 | NIH | 4/4/2025 | $744,480 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R13AI188924 | ThymUS 2025 International Conference on Lymphopoiesis | 000 | 1 | NIH | 11/15/2024 | $3,200 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA262551 | Folic Acid Supplementation and Colitis-associated Colon Carcinogenesis | 001 | 4 | NIH | 5/22/2025 | $64,881 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA262551 | Folic Acid Supplementation and Colitis-associated Colon Carcinogenesis | 000 | 4 | NIH | 4/3/2025 | $583,933 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM119560 | Molecular Mechanisms Underlying Adaptor-Mediated Integrin Signaling in a Species-Specific Manner | 001 | 9 | NIH | 12/10/2024 | $433,373 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM154879 | Mechanistic Studies of Genome Folding | 000 | 2 | NIH | 4/28/2025 | $470,000 |
|
